Compare · JNJ vs RGNT
JNJ vs RGNT
Side-by-side comparison of Johnson & Johnson (JNJ) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. JNJ focuses on Biotechnology: Pharmaceutical Preparations, while RGNT focuses on Industrial Specialties.
- JNJ is the larger of the two at $687.89B, about 79622.1x RGNT ($8.6M).
- JNJ has been more active in the news (14 items in the past 4 weeks vs 2 for RGNT).
- JNJ has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Johnson & Johnson
- Regentis Biomaterials Ltd.
- Price
- -
- -
- Market cap
- $687.89B
- $8.6M
- 1M return
- +12.89%
- -
- 1Y return
- +43.28%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 14
- 2
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
- EVP, Chief Legal Officer Forminard Elizabeth exercised 13,072 shares at a strike of $151.41 and sold $3,717,546 worth of shares (13,072 units at $284.39) (SEC Form 4)
- FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH
- Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
- Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
- Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
- Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
- FDA Approval for RYBREVANT FASPRO issued to JANSSEN BIOTECH
- Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
- Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
Latest RGNT
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
- Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- SEC Form EFFECT filed by Regentis Biomaterials Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- SEC Form POS AM filed by Regentis Biomaterials Ltd.
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update